Valence ロゴ
人気
ログイン
Loading data for SPRY — first visit, this takes a few seconds.

ウォッチリストに追加

ARS Pharmaceuticals Inc.

NasdaqGM: SPRY · リアルタイム株価 · USD
6.38
+0.08 (1.27%)
終値時点： Aug 19, 2026, 5:58 PM

ARS Pharmaceuticals Inc. (SPRY) Stock Price, Analysis & Data

1.27%

データがありません

買気配3.89
時価総額634.47M
売上高（TTM）116.93M
純利益（TTM）-215.43M
ベータ0.97
EPS（TTM）-2.18
PER（TTM）n/a
予想PER-7.17
PBR（TTM）10.34
PSR（TTM）5.43
Earnings DateNov 10, 2026
売気配6.72
出来高543,551
平均出来高（20日）2,061,861
始値6.42
前日終値6.30
当日レンジ6.35 - 6.58
52週レンジ4.91 - 15.09
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

SPRYについて

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Dec 4, 2020
従業員数 195
上場取引所 NasdaqGM
ティッカー SPRY
ウェブサイト https://ars-pharma.com
企業情報の全文

業績

2025年のARS Pharmaceuticalsの売上高は84.28Mで、前年の89.15Mから-5.46%の減少でした。 利益は-171.3Mで、-2,241.76%の減少でした。

財務諸表

決算サプライズ

ARS PharmaceuticalsはAug 13, 2026に四半期決算を発表しました：
  • 売上高は $22.68M で、予想を下回りました $0, うち 184.47% の前年比増加にあたります.
  • EPSは -0.63 で、予想を下回りました -0.14, うち -36.96% の前年比減少.

    • 次回決算発表

    ARS Pharmaceuticals Inc.の決算発表予定日は Nov 10, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    5日前 · Moby

    ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

    Moby summary of ARS Pharmaceuticals, Inc.'s Q2 2026 earnings call

    news image

    5日前 · GuruFocus.com

    ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...

    CEO Donn Casale outlines path to cash flow breakeven by 2027 while navigating slower-than-expected adoption and manufacturing headwinds.

    news image

    5日前 · MarketBeat

    ARS Pharmaceuticals Q2 Earnings Call Highlights

    ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused ...

    news image

    5日前 · Zacks

    ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates

    ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

    news image

    1週間前 · Zacks

    Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

    Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    2ページ中1ページ